IP Library Granted Patent US 8,142,997
Granted Patent B2
US 8,142,997 · App. 12/253,127 · Granted Mar 27, 2012

Mixed cell diagnostic systems for detection of respiratory, herpes and enteric viruses

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,142,997
App. No.
12/253,127
Granted
Mar 27, 2012
Kind
B2
Abstract

The present invention generally relates to the field of diagnostic microbiology, and, more particularly, to compositions and methods for detecting and differentiating one or more viruses or other intracellular parasites present in a specimen. The present invention also provides compositions and methods to evaluate the susceptibility of organisms to antimicrobial agents.

Claims (11)

1. A multiplex method for identifying coronavirus in a sample, comprising the steps of:

a) providing

i) a sample comprising RNA from at least one coronavirus strain, wherein each of said at least one coronavirus strain RNA comprises genomic RNA and subgenomic RNA, wherein said genomic RNA comprises a polymerase gene 1b coding region and a sequence encoding a Spike (S) glycoprotein,

ii) a plurality of primers capable of amplifying said genomic RNA and said subgenomic RNA, wherein said primers are selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, and SEQ ID NO: 11,

b) contacting said genomic and subgenomic RNA from at least one coronavirus strain with said plurality of primers, wherein a reverse transcriptase-polymerase chain reaction creates a first amplicon and a second amplicon;

c) detecting said second amplicon as comprising a coronavirus leader sequence.

2. The method of claim 1 , wherein said coronavirus is the SARS coronavirus.

3. The method of claim 2 , wherein said method further comprises detecting said first amplicon as comprising a region between said polymerase gene 1b coding region and said sequence encoding the said Spike (S) glycoprotein.

4. The method of claim 1 , wherein said sample comprises coronavirus infected cells.

5. The method of claim 1 , further comprising: c) detecting said first and second amplicon on a gel.

6. The method of claim 1 , wherein said leader sequence is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded May 31, 2022
From: BANK OF AMERICA, N.A.
To: QUIDEL CORPORATION
Reel/Frame 060220/0649 →
SECURITY INTEREST Recorded Oct 6, 2017
From: QUIDEL CORPORATION
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 044141/0686 →
CHANGE OF NAME Recorded Mar 21, 2017
From: UNIVERSITY HOSPITALS OF CLEVELAND
To: UNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTER
Reel/Frame 042742/0793 →
CHANGE OF ADDRESS Recorded Jan 12, 2017
From: DIAGNOSTIC HYBRIDS, INC.
To: DIAGNOSTIC HYBRIDS, INC.
Reel/Frame 041351/0846 →
NOTICE OF RELEASE OF GRANT OF PATENT SECURITY INTEREST Recorded Dec 1, 2016
From: BANK OF AMERICA, N.A., AS AGENT
To: DIAGNOSTIC HYBRIDGS, INC.
Reel/Frame 040788/0200 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2012
From: SCHOLL, DAVID R.; GOODRUM, PATRICIA GAIL RAY
To: DIAGNOSTIC HYBRIDS, INC.
Reel/Frame 028034/0414 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2012
From: HUANG, YUNG T.
To: UNIVERSITY HOSPITALS OF CLEVELAND
Reel/Frame 028034/0594 →
GRANT OF PATENT SECURITY INTEREST Recorded Feb 22, 2010
From: DIAGNOSTIC HYBRIDS, INC.
To: BANK OF AMERICA, N.A., AS AGENT
Reel/Frame 023963/0897 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2009
From: SCHOLL, DAVID R.; GOODRUM, PATRICIA GAIL RAY; HUANG, YUNG T.
To: DIAGNOSTIC HYBRIDS, INC.
Reel/Frame 023098/0282 →